10x Genomics, Inc. (TXG)
| Market Cap | 8.48B +410.1% |
| Revenue (ttm) | 616.91M -4.3% |
| Net Income | -75.13M |
| EPS | -0.59 |
| Shares Out | 130.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,249,549 |
| Open | 64.39 |
| Previous Close | 63.87 |
| Day's Range | 61.75 - 65.47 |
| 52-Week Range | 11.16 - 65.47 |
| Beta | 2.04 |
| Analysts | Buy |
| Price Target | 49.54 (-23.93%) |
| Earnings Date | Aug 6, 2026 |
About TXG
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for TXG stock is "Buy." The 12-month stock price target is $49.54, which is a decrease of -23.93% from the latest price.
News
10x Genomics price target raised to $65 from $50 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on 10x Genomics (TXG) to $65 from $50 and keeps an Overweight rating on the shares. The firm is updating its…
10x Genomics price target raised to $60 from $50 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Buy rating on the shares. The firm met with management…
10x Genomics price target raised to $47 from $42 at Piper Sandler
Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $47 from $42 and keeps a Neutral rating on the shares following quarterly results. The firm cites updated…
10x Genomics price target raised to $40 from $37 at Morgan Stanley
Morgan Stanley raised the firm’s price target on 10x Genomics (TXG) to $40 from $37 and keeps an Equal Weight rating on the shares.
10x Genomics price target raised to $50 from $25 at Stifel
Stifel raised the firm’s price target on 10x Genomics (TXG) to $50 from $25 and keeps a Buy rating on the shares.
10x Genomics price target raised to $50 from $45 at Citi
Citi analyst Brendan Digan raised the firm’s price target on 10x Genomics (TXG) to $50 from $45 and keeps a Neutral rating on the shares.
10x Genomics Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% YoY (excluding settlements), driven by strong consumables growth and exceptional demand for the new Atera platform, though instrument sales declined. Full-year guidance was raised, with Atera orders exceeding shipment capacity and AI adoption fueling demand across customer segments.
10x Genomics Earnings release: Q2 2026
10x Genomics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q2 2026
10x Genomics has published its Q2 2026 quarterly earnings report on August 6, 2026.
10x Genomics reports Q2 EPS (14c), consensus (2c)
Reports Q2 revenue $151.0M, consensus $146.61M. “The story of the quarter was the extraordinary customer response to Atera. We are highly encouraged by the engagement across the research ecosystem and...
10x Genomics raises 2026 revenue view to $610M-$630M from $600M-$625M
2026 revenue consensus $614.06M.
10x Genomics Reports Second Quarter 2026 Financial Results
PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financi...
10x Genomics announces research collaboration with Lausanne University Hospital
10x Genomics (TXG) announced a research collaboration with Lausanne University Hospital, or CHUV, one of Switzerland’s leading academic medical centers, to advance research in diagnostic applications ...
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care
Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platforms PLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- ...
10x Genomics price target raised to $40 from $23 at Leerink
Leerink raised the firm’s price target on 10x Genomics (TXG) to $40 from $23 and keeps a Market Perform rating on the shares. The firm cites higher industry multiples. Key…
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...
10x Genomics price target raised to $47 from $25 at TD Cowen
TD Cowen raised the firm’s price target on 10x Genomics (TXG) to $47 from $25 and keeps a Hold rating on the shares. The firm adjusted targets in the tools…
10x Genomics price target raised to $50 from $32 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $50 from $32 and keeps a Buy rating on the shares. The firm updated its model…
10x Genomics price target raised to $37 from $22 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on 10x Genomics (TXG) to $37 from $22 and keeps an Equal Weight rating on the shares. The firm is…
10x Genomics Transcript: Transcript
10x Genomics price target raised to $45 from $24 at Citi
Citi raised the firm’s price target on 10x Genomics (TXG) to $45 from $24 and keeps a Neutral rating on the shares.
10x Genomics price target raised to $40 from $30 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on 10x Genomics (TXG) to $40 from $30 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (O...
10x Genomics announces research collaboration with Cleveland Clinic
10x Genomics (TXG) announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance re...
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ --...